Activation of the Ghrelin Receptor is Described by a Privileged Collective Motion: A Model for Constitutive and Agonist-induced Activation of a Sub-class A G-Protein Coupled Receptor (GPCR)

Journal of Molecular Biology

Volumn 395, Issue 4, 2010, Pages 769-784

  Floquet, Nicolas ^a   M'Kadmi, Céline ^a   Perahia, David ^b   Gagne, Didier ^a   Bergé, Gilbert ^a   Marie, Jacky ^a   Banères, Jean Louis ^a   Galleyrand, Jean Claude ^a   Fehrentz, Jean Alain ^a   Martinez, Jean ^a  

^a UNIVERSITÉ DE MONTPELLIER   (France)

^b INSTITUTE FOR INTEGRATIVE BIOLOGY OF THE CELL I2BC   (France)

Author keywords

activation; ghrelin; GPCR; NMA; receptor

Indexed keywords

1,2,4 TRIAZOLE DERIVATIVE; G PROTEIN COUPLED RECEPTOR; GHRELIN RECEPTOR;

ARTICLE; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENZYME ACTIVE SITE; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STABILITY; SITE DIRECTED MUTAGENESIS;

EID: 73649109875     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2009.09.051     Document Type: Article

References (68)

1. Drews J. Drug discovery: a historical perspective. Science 287 (2000) 1960-1964
2. Howard A.D., Feighner S.D., Cully D.F., Arena J.P., Liberator P.A., Rosenblum C.I., et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273 (1996) 974-977
3. Moulin A., Ryan J., Martinez J., and Fehrentz J.A. Recent developments in ghrelin receptor ligands. Chem. Med. Chem. (2007) 1242-1259
4. Young Cruz C.R., and Smith R.G. The growth hormone secretagogue receptor. Vitam. Horm. 77 (2008) 47-88
5. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., and Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402 (1999) 656-660
6. Yang J., Brown M.S., Liang G., Grishin N.V., and Goldstein J.L. Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 132 (2008) 387-396
7. Bednarek M.A., Feighner S.D., Pong S.S., McKee K.K., Hreniuk D.L., Silva M.V., et al. Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. J. Med. Chem. 43 (2000) 4370-4376
8. Silva Elipe M.V., Bednarek M.A., and Gao Y.D. 1H NMR structural analysis of human ghrelin and its six truncated analogs. Biopolymers 59 (2001) 489-501
9. Beevers A.J., and Kukol A. Conformational flexibility of the peptide hormone ghrelin in solution and lipid membrane bound: a molecular dynamics study. J. Biomol. Struct. Dynam. 23 (2006) 357-364
10. Espinoza-Fonseca L.M., Pedretti A., and Vistoli G. Structure and dynamics of the full-length M1 muscarinic acetylcholine receptor studied by molecular dynamics simulations. Arch. Biochem. Biophys. 469 (2008) 142-150
11. Bhattacharya S., Hall S.E., and Vaidehi N. Agonist-induced conformational changes in bovine rhodopsin: insight into activation of G-protein-coupled receptors. J. Mol. Biol. 382 (2008) 539-555
12. Marco E., Foucaud M., Langer I., Escrieut C., Tikhonova I.G., and Fourmy D. Mechanism of activation of a G protein-coupled receptor, the human cholecystokinin-2 receptor. J. Biol. Chem 282 (2007) 28779-28790
13. Henin J., Maigret B., Tarek M., Escrieut C., Fourmy D., and Chipot C. Probing a model of a GPCR/ligand complex in an explicit membrane environment: the human cholecystokinin-1 receptor. Biophys. J. 90 (2006) 1232-1240
14. Grossfield A., Feller S.E., and Pitman M.C. Convergence of molecular dynamics simulations of membrane proteins. Proteins: Struct Funct. Genet. 67 (2007) 31-40
15. Tikhonova I.G., Best R.B., Engel S., Gershengorn M.C., Hummer G., and Costanzi S. Atomistic insights into rhodopsin activation from a dynamic model. J. Am. Chem. Soc. 130 (2008) 10141-10149
16. Niv M.Y., Skrabanek L., Filizola M., and Weinstein H. Modeling activated states of GPCRs: the rhodopsin template. J. Comput. Aided Mol. Des. 20 (2006) 437-448
17. Park J.H., Scheerer P., Hofmann K.P., Choe H.W., and Ernst O.P. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 454 (2008) 183-187
18. Rosenbaum D.M., Rasmussen S.G., and Kobilka B.K. The structure and function of G-protein-coupled receptors. Nature 459 (2009) 356-363
19. Floquet N., Dedieu S., Martiny L., Dauchez M., and Perahia D. Human thrombospondin's (TSP-1) C-terminal domain opens to interact with the CD-47 receptor: a molecular modeling study. Arch. Biochem. Biophys. 478 (2008) 103-109
20. Floquet N., Durand P., Maigret B., Badet B., Badet-Denisot M.A., and Perahia D. Collective motions in glucosamine-6-phosphate synthase: influence of ligand binding and their role in ammonia channelling and opening of the fructose-6P binding site. J. Mol. Biol. 385 (2009) 653-664
21. Floquet N., Marechal J.D., Badet-Denisot M.A., Robert C.H., Dauchez M., and Perahia D. Normal mode analysis as a prerequisite for drug design: application to matrix metalloproteinases inhibitors. FEBS Lett. 580 (2006) 5130-5136
22. Balog E., Smith J.C., and Perahia D. Conformational heterogeneity and low-frequency vibrational modes of proteins. Phys. Chem. Chem. Phys. 8 (2006) 5543-5548
23. Schwartz T.W., Frimurer T.M., Holst B., Rosenkilde M.M., and Elling C.E. Molecular mechanism of 7TM receptor activation-a global toggle switch model. Annu. Rev. Pharmacol. Toxicol. 46 (2006) 481-519
24. Altenbach C., Cai K., Khorana H.G., and Hubbell W.L. Structural features and light-dependent changes in the sequence 306-322 extending from helix VII to the palmitoylation sites in rhodopsin: a site-directed spin-labeling study. Biochemistry 38 (1999) 7931-7937
25. Altenbach C., Klein-Seetharaman J., Cai K., Khorana H.G., and Hubbell W.L. Structure and function in rhodopsin: mapping light-dependent changes in distance between residue 316 in helix 8 and residues in the sequence 60-75, covering the cytoplasmic end of helices TM1 and TM2 and their connection loop CL1. Biochemistry 40 (2001) 15493-15500
26. Altenbach C., Klein-Seetharaman J., Hwa J., Khorana H.G., and Hubbell W.L. Structural features and light-dependent changes in the sequence 59-75 connecting helices I and II in rhodopsin: a site-directed spin-labeling study. Biochemistry 38 (1999) 7945-7949
27. Crocker E., Eilers M., Ahuja S., Hornak V., Hirshfeld A., Sheves M., and Smith S.O. Location of Trp265 in metarhodopsin II: implications for the activation mechanism of the visual receptor rhodopsin. J. Mol. Biol. 357 (2006) 163-172
28. Patel A.B., Crocker E., Eilers M., Hirshfeld A., Sheves M., and Smith S.O. Coupling of retinal isomerization to the activation of rhodopsin. Proc. Natl Acad. Sci. USA 101 (2004) 10048-10053
29. Dunham T.D., and Farrens D.L. Conformational changes in rhodopsin. Movement of helix f detected by site-specific chemical labeling and fluorescence spectroscopy. J. Biol. Chem. 274 (1999) 1683-1690
30. Farrens D.L., Altenbach C., Yang K., Hubbell W.L., and Khorana H.G. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 274 (1996) 768-770
31. Sheikh S.P., Vilardarga J.P., Baranski T.J., Lichtarge O., Iiri T., Meng E.C., et al. Nissenson, R. A.; Bourne, H. R. Similar structures and shared switch mechanisms of the beta2-adrenoceptor and the parathyroid hormone receptor. Zn(II) bridges between helices III and VI block activation. J. Biol. Chem. 274 (1999) 17033-17041
32. Struthers M., Yu H., and Oprian D.D. G protein-coupled receptor activation: analysis of a highly constrained, "straitjacketed" rhodopsin. Biochemistry 39 (2000) 7938-7942
33. Yu H., and Oprian D.D. Tertiary interactions between transmembrane segments 3 and 5 near the cytoplasmic side of rhodopsin. Biochemistry 38 (1999) 12033-12040
34. Shi L., Liapakis G., Xu R., Guarnieri F., Ballesteros J.A., and Javitch J.A. Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J. Biol. Chem. 277 (2002) 40989-40996
35. Huang P., Li J., Chen C., Visiers I., Weinstein H., and Liu-Chen L.Y. Functional role of a conserved motif in TM6 of the rat mu opioid receptor: constitutively active and inactive receptors result from substitutions of Thr6.34(279) with Lys and Asp. Biochemistry 40 (2001) 13501-13509
36. Huang P., Visiers I., Weinstein H., and Liu-Chen L.Y. The local environment at the cytoplasmic end of TM6 of the mu opioid receptor differs from those of rhodopsin and monoamine receptors: introduction of an ionic lock between the cytoplasmic ends of helices 3 and 6 by a L6.30(275)E mutation inactivates the mu opioid receptor and reduces the constitutive activity of its T6.34(279)K mutant. Biochemistry 41 (2002) 11972-11980
37. Vogel R., Mahalingam M., Ludeke S., Huber T., Siebert F., and Sakmar T.P. Functional role of the "ionic lock"-an interhelical hydrogen-bond network in family A heptahelical receptors. J. Mol. Biol. 380 (2008) 648-655
38. Lin S.W., and Sakmar T.P. Specific tryptophan UV-absorbance changes are probes of the transition of rhodopsin to its active state. Biochemistry 35 (1996) 11149-11159
39. Holst B., Holliday N.D., Bach A., Elling C.E., Cox H.M., and Schwartz T.W. Common structural basis for constitutive activity of the ghrelin receptor family. J. Biol. Chem. 279 (2004) 53806-53817
40. Feighner S.D., Howard A.D., Prendergast K., Palyha O.C., Hreniuk D.L., Nargund R., et al. Structural requirements for the activation of the human growth hormone secretagogue receptor by peptide and nonpeptide secretagogues. Mol. Endocrinol. 12 (1998) 137-145
41. Holst B., Mokrosinski J., Lang M., Brandt E., Nygaard R., Frimurer T.M., et al. Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J. Biol. Chem. 282 (2007) 15799-15811
42. Liu G., Fortin J.P., Beinborn M., and Kopin A.S. Four missense mutations in the ghrelin receptor result in distinct pharmacological abnormalities. J. Pharmacol. Exp. Ther. 322 (2007) 1036-1043
43. Pantel J., Legendre M., Cabrol S., Hilal L., Hajaji Y., Morisset S., et al. Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. J. Clin. Invest. 116 (2006) 760-768
44. Moulin A., Demange L., Berge G., Gagne D., Ryan J., Mousseaux D., et al. Toward potent ghrelin receptor ligands based on trisubstituted 1,2,4-triazole structure. 2. Synthesis and pharmacological in vitro and in vivo evaluations. J. Med. Chem. 50 (2007) 5790-5806
45. Moulin A., Demange L., Ryan J., M'Kadmi C., Galleyrand J.C., Martinez J., and Fehrentz J.A. Trisubstituted 1,2,4-triazoles as ligands for the ghrelin receptor: on the significance of the orientation and substitution at position 3. Bioorg. Med. Chem. Lett. 18 (2008) 164-168
46. Moulin A., Demange L., Ryan J., Mousseaux D., Sanchez P., Berge G., et al. New trisubstituted 1,2,4-triazole derivatives as potent ghrelin receptor antagonists. 3. Synthesis and pharmacological in vitro and in vivo evaluations. J. Med. Chem. 51 (2008) 689-693
47. Tirado-Rives J., and Jorgensen W.L. Contribution of conformer focusing to the uncertainty in predicting free energies for protein-ligand binding. J. Med. Chem. 49 (2006) 5880-5884
48. Cavasotto C.N., Orry A.J.W., Murgolo N.J., Czarniecki M.F., Kocsi S.A., Hawes B.E., et al. Discovery of novel chemotypes to a G-Protein-Coupled Receptor through ligand-steered homology modeling and structure-based virtual screening. J. Med. Chem. 51 (2008) 581-588
49. Clayton A.H., and Sawyer W.H. Tryptophan rotamer distributions in amphipathic peptides at a lipid surface. Biophys. J. 76 (1999) 3235-3242
50. Cavasotto C.N., and Abagyan R.A. Protein flexibility in ligand docking and virtual screening to protein kinases. J. Mol. Biol. 337 (2004) 209-225
51. Kobilka B.K., and Deupi X. Conformational complexity of G-protein-coupled receptors. Trends Pharmacol. Sci. 28 (2007) 397-406
52. Thompson J.D., Gibson T.J., Plewniak F., Jeanmougin F., and Higgins D.G. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 25 (1997) 4876-4882
53. Sali A., and Blundell T.L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234 (1993) 779-815
54. Mantel N. The detection of disease clustering and a generalized regression approach. Cancer Res 27 (1967) 209-220
55. Brooks B.R., Bruccoleri R.E., Olafson B.D., States D.J., Swaminathan S., and Karplus M. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 4 (1983) 187-217
56. MacKerell A.D., Bashford D., Bellott M., Dunbrack R.L., Evanseck J.D., Field M.J., et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B 102 (1998) 3586-3616
57. Phillips J.C., Braun R., Wang W., Gumbart J., Tajkhorshid E., Villa E., et al. Scalable molecular dynamics with NAMD. J. Comput. Chem. 26 (2005) 1781-1802
58. Darden T.A., York D.M., and Pedersen L.G. Particle mesh Ewald. An N.log(N) method for Ewald sums in large systems. J. Chem. Phys. 98 (1993) 10089-10092
59. Jorgensen W.L., Chandrasekhar J., and Madura J.D. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79 (1983) 926-935
60. Humphrey W., Dalke A., and Schulten K. VMD: visual molecular dynamics. J. Mol. Graph. 14 (1996) 33-38
61. Perahia D., and Mouawad L. Computation of low-frequency normal modes in macromolecules: improvements to the method of diagonalization in a mixed basis and application to hemoglobin. Comput. Chem. 19 (1995) 241-246
62. Fisher C.L., and Pei G.K. Modification of a PCR-based site-directed mutagenesis method. Biotechniques 23 (1997) 570-574
63. Guerlavais V., Boeglin D., Mousseaux D., Oiry C., Heitz A., Deghenghi R., et al. New active series of growth hormone secretagogues. J. Med. Chem. 46 (2003) 1191-1203
64. Mousseaux D., Le Gallic L., Ryan J., Oiry C., Gagne D., Fehrentz J.A., et al. Regulation of ERK1/2 activity by ghrelin-activated growth hormone secretagogue receptor 1A involves a PLC/PKCvarepsilon pathway. Br. J. Pharmacol. 148 (2006) 350-365
65. Astruc M.E., Chabret C., Bali P., Gagne D., and Pons M. Prolonged treatment of breast cancer cells with antiestrogens increases the activating protein-1-mediated response: involvement of the estrogen receptor. Endocrinology 136 (1995) 824-832
66. Verdonk M.L., Cole J.C., Hartshorn M.J., Murray C.W., and Taylor R.D. Improved protein-ligand docking using GOLD. Proteins: Struct. Funct. Genet. 52 (2003) 609-623
67. The R project for statistical computing (http://www.r-project.org/).
68. Floquet N., Hery-Huynh S., Dauchez M., Derreumaux P., Tamburro A.M., and Alix A.J. Structural characterization of VGVAPG, an elastin-derived peptide. Biopolymers 76 (2004) 266-280